S&P 500   3,900.79 (-0.58%)
DOW   31,253.13 (-0.75%)
QQQ   289.58 (-0.54%)
AAPL   137.35 (-2.46%)
MSFT   253.14 (-0.37%)
FB   191.29 (-0.49%)
GOOGL   2,207.68 (-1.35%)
AMZN   2,146.38 (+0.19%)
TSLA   709.42 (-0.05%)
NVDA   171.24 (+1.10%)
BABA   87.69 (+0.44%)
NIO   16.66 (+5.24%)
AMD   96.67 (+0.41%)
CGC   5.87 (+5.01%)
MU   69.40 (-2.32%)
T   20.21 (-0.10%)
GE   75.74 (+0.72%)
F   12.85 (+0.55%)
DIS   103.14 (-1.11%)
AMC   13.08 (+2.51%)
PFE   50.65 (+0.50%)
PYPL   81.28 (+5.31%)
NFLX   183.48 (+3.55%)
S&P 500   3,900.79 (-0.58%)
DOW   31,253.13 (-0.75%)
QQQ   289.58 (-0.54%)
AAPL   137.35 (-2.46%)
MSFT   253.14 (-0.37%)
FB   191.29 (-0.49%)
GOOGL   2,207.68 (-1.35%)
AMZN   2,146.38 (+0.19%)
TSLA   709.42 (-0.05%)
NVDA   171.24 (+1.10%)
BABA   87.69 (+0.44%)
NIO   16.66 (+5.24%)
AMD   96.67 (+0.41%)
CGC   5.87 (+5.01%)
MU   69.40 (-2.32%)
T   20.21 (-0.10%)
GE   75.74 (+0.72%)
F   12.85 (+0.55%)
DIS   103.14 (-1.11%)
AMC   13.08 (+2.51%)
PFE   50.65 (+0.50%)
PYPL   81.28 (+5.31%)
NFLX   183.48 (+3.55%)
S&P 500   3,900.79 (-0.58%)
DOW   31,253.13 (-0.75%)
QQQ   289.58 (-0.54%)
AAPL   137.35 (-2.46%)
MSFT   253.14 (-0.37%)
FB   191.29 (-0.49%)
GOOGL   2,207.68 (-1.35%)
AMZN   2,146.38 (+0.19%)
TSLA   709.42 (-0.05%)
NVDA   171.24 (+1.10%)
BABA   87.69 (+0.44%)
NIO   16.66 (+5.24%)
AMD   96.67 (+0.41%)
CGC   5.87 (+5.01%)
MU   69.40 (-2.32%)
T   20.21 (-0.10%)
GE   75.74 (+0.72%)
F   12.85 (+0.55%)
DIS   103.14 (-1.11%)
AMC   13.08 (+2.51%)
PFE   50.65 (+0.50%)
PYPL   81.28 (+5.31%)
NFLX   183.48 (+3.55%)
S&P 500   3,900.79 (-0.58%)
DOW   31,253.13 (-0.75%)
QQQ   289.58 (-0.54%)
AAPL   137.35 (-2.46%)
MSFT   253.14 (-0.37%)
FB   191.29 (-0.49%)
GOOGL   2,207.68 (-1.35%)
AMZN   2,146.38 (+0.19%)
TSLA   709.42 (-0.05%)
NVDA   171.24 (+1.10%)
BABA   87.69 (+0.44%)
NIO   16.66 (+5.24%)
AMD   96.67 (+0.41%)
CGC   5.87 (+5.01%)
MU   69.40 (-2.32%)
T   20.21 (-0.10%)
GE   75.74 (+0.72%)
F   12.85 (+0.55%)
DIS   103.14 (-1.11%)
AMC   13.08 (+2.51%)
PFE   50.65 (+0.50%)
PYPL   81.28 (+5.31%)
NFLX   183.48 (+3.55%)
NASDAQ:SMMT

Summit Therapeutics (SMMT) Stock Forecast, Price & News

$1.02
+0.01 (+0.99%)
(As of 05/19/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.01
$1.04
50-Day Range
$1.01
$3.45
52-Week Range
$1.00
$8.70
Volume
76,344 shs
Average Volume
124,390 shs
Market Capitalization
$100.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.99
30 days | 90 days | 365 days | Advanced Chart
Receive SMMT News and Ratings via Email

Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Summit Therapeutics logo

About Summit Therapeutics

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.

Headlines

SMMT Summit Therapeutics Inc.
Summit Therapeutics Inc. Common Stock (SMMT)
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SMMT
Employees
105
Year Founded
N/A

Sales & Book Value

Annual Sales
$22.78 million
Book Value
$0.66 per share

Profitability

Net Income
$-88.60 million
Net Margins
-735.61%
Pretax Margin
-735.61%

Debt

Price-To-Earnings

Miscellaneous

Free Float
24,737,000
Market Cap
$100.08 million
Optionable
Optionable

Company Calendar

Last Earnings
3/17/2022
Today
5/19/2022
Next Earnings (Estimated)
8/10/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.13 out of 5 stars

Medical Sector

1200th out of 1,418 stocks

Pharmaceutical Preparations Industry

587th out of 677 stocks

Analyst Opinion: 0.0Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -













Summit Therapeutics (NASDAQ:SMMT) Frequently Asked Questions

Is Summit Therapeutics a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Summit Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Summit Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SMMT, but not buy additional shares or sell existing shares.
View analyst ratings for Summit Therapeutics
or view top-rated stocks.

When is Summit Therapeutics' next earnings date?

Summit Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for Summit Therapeutics
.

How were Summit Therapeutics' earnings last quarter?

Summit Therapeutics Inc. (NASDAQ:SMMT) announced its quarterly earnings data on Thursday, March, 17th. The company reported ($0.28) earnings per share (EPS) for the quarter. The company had revenue of $4.84 million for the quarter. Summit Therapeutics had a negative trailing twelve-month return on equity of 100.17% and a negative net margin of 735.61%.
View Summit Therapeutics' earnings history
.

Who are Summit Therapeutics' key executives?
Summit Therapeutics' management team includes the following people:
  • Mr. Robert W. Duggan, Exec. Chairman, CEO & Interim Principal Financial Officer (Age 77) (LinkedIn Profile)
  • Dr. Mahkam Zanganeh D.D.S., M.B.A., MBA, COO & Director (Age 52, Pay $459.38k)
  • Prof. Dame Kay Davies DBE, FRS CBE, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor (Age 71)
  • Ms. Michelle Avery, Director of Investor Relations
  • Mr. Dave Gancarz, Head of Investor Relations & Corp. Strategy
  • Dr. Elaine Stracker, Gen. Counsel? (Age 61)
  • Mr. Campbell Hair, Head of HR?
  • Dr. Jonathon Tinsley, Chief Scientific Officer of DMD (Age 63)
  • Dr. Anne Heatherington, Head of Clinical Devel. and Quantitative Sciences
  • Ms. Divya Chari, Head of Global Clinical Operations (Age 54)
What other stocks do shareholders of Summit Therapeutics own?
When did Summit Therapeutics IPO?

(SMMT) raised $40 million in an initial public offering (IPO) on Thursday, March 5th 2015. The company issued 3,500,000 shares at a price of $11.54 per share. JMP Securities and Oppenheimer & Co. acted as the underwriters for the IPO and Needham was co-manager.

What is Summit Therapeutics' stock symbol?

Summit Therapeutics trades on the NASDAQ under the ticker symbol "SMMT."

Who are Summit Therapeutics' major shareholders?

Summit Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Polar Capital Holdings Plc (6.39%), BlackRock Inc. (1.39%), State Street Corp (0.32%), Northern Trust Corp (0.18%), UBS Group AG (0.08%) and Goldman Sachs Group Inc. (0.04%). Company insiders that own Summit Therapeutics stock include David Jonathan Powell, Maky Zanganeh and Robert W Duggan.
View institutional ownership trends for Summit Therapeutics
.

Which major investors are selling Summit Therapeutics stock?

SMMT stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., UBS Group AG, State Street Corp, Northern Trust Corp, Goldman Sachs Group Inc., JPMorgan Chase & Co., Simplex Trading LLC, and Group One Trading L.P..
View insider buying and selling activity for Summit Therapeutics
or view top insider-selling stocks.

Which major investors are buying Summit Therapeutics stock?

SMMT stock was purchased by a variety of institutional investors in the last quarter, including Polar Capital Holdings Plc. Company insiders that have bought Summit Therapeutics stock in the last two years include Maky Zanganeh, and Robert W Duggan.
View insider buying and selling activity for Summit Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Summit Therapeutics?

Shares of SMMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Summit Therapeutics' stock price today?

One share of SMMT stock can currently be purchased for approximately $1.02.

How much money does Summit Therapeutics make?

Summit Therapeutics has a market capitalization of $100.08 million and generates $22.78 million in revenue each year. The company earns $-88.60 million in net income (profit) each year or ($0.970010) on an earnings per share basis.

How many employees does Summit Therapeutics have?

Summit Therapeutics employs 105 workers across the globe.

What is Summit Therapeutics' official website?

The official website for Summit Therapeutics is www.summitplc.com.

How can I contact Summit Therapeutics?

Summit Therapeutics' mailing address is 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB. The company can be reached via phone at 617-514-7149, via email at [email protected], or via fax at 44-12-3544-3999.

This page was last updated on 5/19/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.